D C Saltman1, G P Sayer, S D Whicker. 1. University of Sydney, 37A Booth Street, Balmain 2041, NSW, Australia. deborah@gp.med.usyd.edu.au
Abstract
BACKGROUND: Co-morbidity, or the presence of more than one clinical condition, is gaining increased attention in epidemiological and health services research. However, the clinical relevance of co-morbidity has yet to be defined. In general practice, few studies have been conducted into co-morbidity, either at a single health care encounter, an episode of care, or for a defined time period. AIMS: To describe the major co-morbidity cluster profiles recorded by general practitioners. Another aim of this study is to describe the common clusters of co-prescribing. METHODS AND RESULTS: Twelve month data from patients attending 156 GPs from 95 practices around a six month period of January to June 2003 were analysed. This represented 840,961 encounters from about 200,000 individual patients at these participating practices. Co-morbidity and co-prescribing cluster profiles are represented by problems managed and reasons for prescribing for the top 10 presentations and top 10 prescribed drugs in the study period. CONCLUSIONS: By analysing the 10 most prevalent problems and 10 most prevalent drugs prescribed in consultations in a community sample, other co-morbidities that are particular to general practice, for example hypertension and lipid disorders, can be uncovered. Whether these clusters are causally related or occur by chance requires further analysis.
BACKGROUND: Co-morbidity, or the presence of more than one clinical condition, is gaining increased attention in epidemiological and health services research. However, the clinical relevance of co-morbidity has yet to be defined. In general practice, few studies have been conducted into co-morbidity, either at a single health care encounter, an episode of care, or for a defined time period. AIMS: To describe the major co-morbidity cluster profiles recorded by general practitioners. Another aim of this study is to describe the common clusters of co-prescribing. METHODS AND RESULTS: Twelve month data from patients attending 156 GPs from 95 practices around a six month period of January to June 2003 were analysed. This represented 840,961 encounters from about 200,000 individual patients at these participating practices. Co-morbidity and co-prescribing cluster profiles are represented by problems managed and reasons for prescribing for the top 10 presentations and top 10 prescribed drugs in the study period. CONCLUSIONS: By analysing the 10 most prevalent problems and 10 most prevalent drugs prescribed in consultations in a community sample, other co-morbidities that are particular to general practice, for example hypertension and lipid disorders, can be uncovered. Whether these clusters are causally related or occur by chance requires further analysis.
Authors: Matthew T Gettman; Christopher W Boelter; John C Cheville; Horst Zincke; Sandra C Bryant; Michael L Blute Journal: J Urol Date: 2003-04 Impact factor: 7.450
Authors: Tarja K Melartin; Heikki J Rytsälä; Ulla S Leskelä; Paula S Lestelä-Mielonen; T Petteri Sokero; Erkki T Isometsä Journal: J Clin Psychiatry Date: 2002-02 Impact factor: 4.384
Authors: Barbara Starfield; Klaus W Lemke; Terence Bernhardt; Steven S Foldes; Christopher B Forrest; Jonathan P Weiner Journal: Ann Fam Med Date: 2003 May-Jun Impact factor: 5.166
Authors: Paul A Scuffham; Michael F Hilton; Alexander Muspratt; Shu-Kay Ng; Harvey A Whiteford; Libby Holden Journal: Popul Health Metr Date: 2011-06-02
Authors: Concepción Violán; Quintí Foguet-Boreu; Albert Roso-Llorach; Teresa Rodriguez-Blanco; Mariona Pons-Vigués; Enriqueta Pujol-Ribera; Miguel Ángel Muñoz-Pérez; Jose M Valderas Journal: BMC Public Health Date: 2014-05-29 Impact factor: 3.295